Allogenic Synovia-Derived Mesenchymal Stem Cells for Treatment of Equine Tendinopathies and Desmopathies-Proof of Concept.
Authors: Leal Reis Inês, Lopes Bruna, Sousa Patrícia, Sousa Ana Catarina, Branquinho Mariana, Caseiro Ana Rita, Pedrosa Sílvia Santos, Rêma Alexandra, Oliveira Cláudia, Porto Beatriz, Atayde Luís, Amorim Irina, Alvites Rui, Santos Jorge Miguel, Maurício Ana Colette
Journal: Animals : an open access journal from MDPI
Summary
# Editorial Summary Tendon and ligament injuries remain a persistent challenge in equine medicine, prompting investigation into regenerative therapeutic options beyond conventional management. Researchers isolated and characterised mesenchymal stem cells derived from equine synovial membrane (eSM-MSCs), confirming their fibroblast-like morphology and capacity for osteogenic, chondrogenic, and adipogenic differentiation before delivering allogenic cells suspended in autologous serum to 16 clinical cases of tendonitis and desmitis. Fourteen of the 16 cases (87.5%) demonstrated successful healing within 30 days, suggesting that the combination approach—leveraging both the regenerative potential of MSCs and the growth factors and immunoglobulins present in autologous serum—may reduce adverse immunogenic responses whilst promoting tissue repair. The use of allogenic rather than autologous cells offers practical advantages for practitioners, circumventing delays associated with isolation and expansion from individual animals and enabling off-the-shelf availability for acute presentations. Whilst this proof-of-concept work is encouraging, wider prospective controlled trials comparing this approach against standard treatments and longer-term follow-up data will be necessary to establish efficacy, durability of repair, and optimal protocols for clinical adoption across varied tendon and ligament injuries in sport horses.
Read the full abstract on PubMed
Practical Takeaways
- •Allogenic stem cell therapy combined with autologous serum shows promise as a clinical treatment option for tendon and ligament injuries in sport horses, with the majority of cases healing within one month
- •This approach may offer advantages over some alternatives due to reduced immune rejection risk when using allogenic cells with autologous serum as the vehicle
- •Practitioners should note this is proof-of-concept work; further controlled trials comparing outcomes to standard treatments and longer-term follow-up data would strengthen clinical adoption
Key Findings
- •Equine synovial membrane mesenchymal stem cells (eSM-MSCs) were successfully isolated, characterized, and retained osteogenic, chondrogenic, and adipogenic differentiation potential
- •14 of 16 clinical cases (87.5%) treated with allogenic eSM-MSCs combined with autologous serum healed within 30 days with good outcomes
- •The combination of eSM-MSCs and autologous serum reduced immunogenic response while providing pro-regenerative effects from growth factors and immunoglobulins